Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on SHR2554 PK in Healthy Chinese Adults
NCT04577885Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in Mature lymphoid neoplasms, peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SHR2554 and Area Under the Plasma Concentration-Time Curve of SHR2554. Started May 2020; status: completed.
02
Drugs
zeprumetostat
03
Conditions
Mature lymphoid neoplasmsperipheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04577885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577885.